Hepion in-licenses ctRNA biomarker assay for early HCC detection from Cirna Diagnostics

Hepion Pharmaceuticals, Inc.

Upfront $50K, milestones up to $2.35M, sales milestones up to $4.5M, low single-digit royalty.
Assay detects mutant circulating tumor RNA (ctRNA) for early HCC diagnosis in high-risk cirrhosis patients.
Complements Hepion's mSEPT9 PCR assay; strategic shift to liquid biopsy diagnostics.
Global liquid biopsy market ~$10B; plans CLIA lab partnerships and eventual FDA submission.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Hepion Pharmaceuticals, Inc. entered into intellectual property license agreement with Cirna Diagnostics, LLC valued at upfront payment of $50,000 as well as certain patent expenses, up to $2,350,000 in milestone payment (effective 2026-02-25).

Action: entry
Agreement: license
Counterparty: Cirna Diagnostics, LLC
Value: upfront payment of $50,000 as well as certain patent expenses, up to $2,350,000 in milestone payment
Effective: 2026-02-25

Exact text from the filing

On February 25, 2026, Hepion Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), entered into an intellectual property license agreement with Cirna Diagnostics, LLC (“ Cirna ”) pursuant to which the Company licensed certain liver disease diagnostic assets from Cirna.

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

Hepion Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-008650

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.